$MD
Pediatrix Medical Group, Inc. Stock $md

$md Overview Financials Valuation SEC Filings Company Website

2015 Form 10-K Financial Statement

#000119312516459842 Filed on February 11, 2016

Income Statement

Concept	2015	2014 Q4	2014 Q3
Revenue	$2.780B	$650.5M	$626.5M
YoY Change	13.99%	14.65%	12.94%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.059B	$472.0M	$455.4M
YoY Change	14.99%	15.4%	13.42%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$64.23M	$13.90M	$11.36M
YoY Change	39.66%	32.52%	8.56%
% of Gross Profit
Operating Expenses	$2.222B	$509.4M	$488.4M
YoY Change	15.38%	14.88%	13.19%
Operating Profit	$557.9M	$141.1M	$138.1M
YoY Change	8.75%	13.86%	12.05%
Interest Expense	$23.11M	$3.313M	$2.019M
YoY Change	159.93%	216.73%	33.97%
% of Operating Profit	4.14%	2.35%	1.46%
Other Income/Expense, Net	-$18.14M	-$2.213M	-$731.0K
YoY Change	313.85%		-35.59%
Pretax Income	$539.7M	$138.9M	$137.4M
YoY Change	6.12%	12.54%	12.49%
Income Tax	$204.0M	$50.59M	$51.17M
% Of Pretax Income	37.8%	36.43%	37.24%
Net Earnings	$336.3M	$88.40M	$86.21M
YoY Change	6.0%	11.93%	12.02%
Net Earnings / Revenue	12.1%	13.59%	13.76%
Basic Earnings Per Share	$3.61	$0.90	$0.87
Diluted Earnings Per Share	$3.58	$0.89	$0.86
COMMON SHARES
Basic Shares Outstanding	93.08M shares	98.07M shares	99.09M shares
Diluted Shares Outstanding	93.96M shares	99.13M shares	100.1M shares

Balance Sheet

Concept	2015	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$60.40M	$54.00M	$79.10M
YoY Change	11.85%	43.62%	273.11%
Cash & Equivalents	$51.60M	$47.93M	$71.82M
Short-Term Investments	$8.900M	$6.000M	$7.300M
Other Short-Term Assets	$22.60M	$7.901M	$10.82M
YoY Change	-62.89%	-1.32%	14.9%
Inventory
Prepaid Expenses		$7.036M	$8.778M
Receivables	$444.7M	$352.2M	$345.2M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$527.8M	$467.1M	$481.1M
YoY Change	13.0%	26.87%	28.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$83.60M	$66.05M	$63.60M
YoY Change	26.67%	10.24%	4.37%
Goodwill		$2.776B	$2.659B
YoY Change		15.98%	12.96%
Intangibles		$198.1M
YoY Change
Long-Term Investments	$63.30M	$64.10M	$61.80M
YoY Change	-1.25%	11.48%	0.0%
Other Assets	$82.20M	$36.74M	$212.4M
YoY Change	123.98%	-71.61%	63.45%
Total Long-Term Assets	$4.019B	$3.141B	$2.997B
YoY Change	27.96%	18.96%	14.97%
TOTAL ASSETS
Total Short-Term Assets	$527.8M	$467.1M	$481.1M
Total Long-Term Assets	$4.019B	$3.141B	$2.997B
Total Assets	$4.547B	$3.608B	$3.478B
YoY Change	26.02%	19.93%	16.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$22.00M	$32.78M	$22.17M
YoY Change	-32.93%	76.21%	93.25%
Accrued Expenses	$373.8M	$347.9M	$278.1M
YoY Change	7.44%	19.92%	13.46%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.90M	$10.00M	$300.0K
YoY Change	13.33%	9900.0%	200.0%
Total Short-Term Liabilities	$428.8M	$416.3M	$329.3M
YoY Change	3.0%	27.38%	20.18%
LONG-TERM LIABILITIES
Long-Term Debt	$1.263B	$557.5M	$288.2M
YoY Change	126.19%	1964.64%	132.98%
Other Long-Term Liabilities	$228.8M	$58.96M	$54.51M
YoY Change	10.21%	-3.32%	-13.91%
Total Long-Term Liabilities	$1.492B	$616.4M	$54.51M
YoY Change	94.75%	600.59%	-13.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$428.8M	$416.3M	$329.3M
Total Long-Term Liabilities	$1.492B	$616.4M	$54.51M
Total Liabilities	$2.110B	$1.343B	$973.1M
YoY Change	57.02%	101.69%	30.48%
SHAREHOLDERS EQUITY
Retained Earnings		$1.377B	$1.604B
YoY Change		-7.23%	14.19%
Common Stock		$887.8M	$1.003M
YoY Change		87630.93%	99.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.438B	$2.265B	$2.504B
YoY Change
Total Liabilities & Shareholders Equity	$4.547B	$3.608B	$3.478B
YoY Change	26.02%	19.93%	16.72%

Cashflow Statement

Concept	2015	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	$336.3M	$88.40M	$86.21M
YoY Change	6.0%	11.93%	12.02%
Depreciation, Depletion And Amortization	$64.23M	$13.90M	$11.36M
YoY Change	39.66%	32.52%	8.56%
Cash From Operating Activities	$368.7M	$178.8M	$159.4M
YoY Change	-12.75%	28.36%	0.95%
INVESTING ACTIVITIES
Capital Expenditures	-$27.10M	-$6.700M	-$3.600M
YoY Change	49.72%	123.33%	5.88%
Acquisitions	$818.9M
YoY Change	70.82%
Other Investing Activities	-$820.9M	-$134.3M	-$214.0M
YoY Change	69.08%	222.06%	179.74%
Cash From Investing Activities	-$848.0M	-$141.0M	-$217.7M
YoY Change	68.39%	215.44%	172.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$214.9M
YoY Change	-51.76%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	482.9M	-61.60M	112.3M
YoY Change	393.76%	-22.71%	-249.73%
NET CHANGE
Cash From Operating Activities	368.7M	178.8M	159.4M
Cash From Investing Activities	-848.0M	-141.0M	-217.7M
Cash From Financing Activities	482.9M	-61.60M	112.3M
Net Change In Cash	3.600M	-23.80M	54.00M
YoY Change	-78.57%	-259.73%	1641.94%
FREE CASH FLOW
Cash From Operating Activities	$368.7M	$178.8M	$159.4M
Capital Expenditures	-$27.10M	-$6.700M	-$3.600M
Free Cash Flow	$395.8M	$185.5M	$163.0M
YoY Change	-10.19%	30.36%	1.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	600000000
CY2014Q2	md	Number Of Joint Ventures NumberOfJointVentures	2	JointVenture
CY2015Q1	us-gaap	Accelerated Share Repurchases Settlement Payment Or Receipt AcceleratedShareRepurchasesSettlementPaymentOrReceipt	200000000
CY2015Q2	dei	Entity Public Float EntityPublicFloat	6829814854
CY2015Q2	md	Line Of Credit Facility Potential Increase In Borrowing Capacity LineOfCreditFacilityPotentialIncreaseInBorrowingCapacity	2200000000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13072000
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2035368000
CY2012Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	137036000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21280000
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14902000
CY2013Q4	us-gaap	Income Tax Examination Increase Decrease In Liability From Prior Year IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear	-600000
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2342988000
CY2013Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	158691000
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	16900000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31137000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	814094	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.57
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1271044	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	46.80
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96030000	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96030000	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	368000000
CY2014Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	114526000
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	886877000
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	29899000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	2264619000
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	557453000
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	10465000
CY2014Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	1320000
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	58963000
CY2014Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	35300000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	100932000
CY2014Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	25150000
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	567453000
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	380658000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17165000
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	10000000
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	32783000
CY2014Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	231390000
CY2014Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Noncurrent MalpracticeLossContingencyAccrualUndiscountedNoncurrent	148651000
CY2014Q4	us-gaap	Income Tax Examination Increase Decrease In Liability From Prior Year IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear	300000
CY2014Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	38524000
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	848767000
CY2014Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	120600000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1376782000
CY2014Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Current MalpracticeLossContingencyAccrualUndiscountedCurrent	19718000
CY2014Q4	us-gaap	Liabilities Liabilities	1342682000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3608248000
CY2014Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	8700000
CY2014Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	568000000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	960000
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2265566000
CY2014Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	253684000
CY2014Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	192000
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	96895000
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9200000
CY2014Q4	us-gaap	Minority Interest MinorityInterest	947000
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	416273000
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	160487000
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	465000
CY2014Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	855000
CY2014Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	168369000
CY2014Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	16000000
CY2014Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	547000
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10933000
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1524000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	36742000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14354000
CY2014Q4	us-gaap	Assets Assets	3608248000
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	198136000
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	352191000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	66048000
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	139158000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	69100000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	467052000
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	7901000
CY2014Q4	us-gaap	Land Land	6683000
CY2014Q4	us-gaap	Accelerated Share Repurchases Settlement Payment Or Receipt AcceleratedShareRepurchasesSettlementPaymentOrReceipt	200000000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	48178000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	299068000
CY2014Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	29000000
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1461000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	62708000
CY2014Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	22981000
CY2014Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	5100000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	198136000
CY2014Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	133279000
CY2014Q4	us-gaap	Goodwill Goodwill	2776188000
CY2014Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	6035000
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7036000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47928000
CY2014Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	64082000
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	162943000
CY2014Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	45961000
CY2014Q4	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	54959000
CY2014Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1200958000
CY2014Q4	us-gaap	Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount	9123000
CY2014Q4	md	Unamortized Debt Issuance Expense Noncurrent UnamortizedDebtIssuanceExpenseNoncurrent	547000
CY2014Q4	md	Debt Instrument Face Amount Non Current DebtInstrumentFaceAmountNonCurrent	558000000
CY2014Q4	md	Debt Instrument Face Amount Current DebtInstrumentFaceAmountCurrent	10000000
CY2014Q4	md	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	214968000
CY2014Q4	md	Accrued Professional Liability AccruedProfessionalLiability	47800000
CY2014Q4	md	Unamortized Debt Issuance Expense Current UnamortizedDebtIssuanceExpenseCurrent	0
CY2014Q4	md	Intangible Assets And Other Assets Noncurrent IntangibleAssetsAndOtherAssetsNoncurrent	234878000
CY2014Q4	md	Accrued Payroll Taxes And Benefits Current AccruedPayrollTaxesAndBenefitsCurrent	49858000
CY2014Q4	md	Accrued Contingent Consideration Liability Current AccruedContingentConsiderationLiabilityCurrent	17010000
CY2014Q4	md	Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent	380658000
CY2014Q4	md	Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit	190308000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	585387	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.96
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1013791	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	61.50
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93739000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5400000	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	585387	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	93739000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	27.96
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	23045000
CY2015Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	10000000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	29856000
CY2015Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	343500000
CY2015Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	154005000
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	926235000
CY2015Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	20000000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	34800000
CY2015Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	1400000000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	101761000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	2437528000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	7402000
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1260404000
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	11883000
CY2015Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	4299000
CY2015Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	30000000
CY2015Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh	4000000
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	52289000
CY2015Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	24900000
CY2015Q4	us-gaap	Increase In Unrecognized Tax Benefits Is Reasonably Possible IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	2500000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	142976000
CY2015Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	21081000
CY2015Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	130000000
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	1270404000
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	395807000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18447000
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	10000000
CY2015Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	17100000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	21969000
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	233499000
CY2015Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Noncurrent MalpracticeLossContingencyAccrualUndiscountedNoncurrent	176532000
CY2015Q4	us-gaap	Income Tax Examination Increase Decrease In Liability From Prior Year IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear	600000
CY2015Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	55046000
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	1632000
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1129301000
CY2015Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	142400000
CY2015Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value Low BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow	0
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1510356000
CY2015Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Current MalpracticeLossContingencyAccrualUndiscountedCurrent	25995000
CY2015Q4	us-gaap	Liabilities Liabilities	2109368000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4547214000
CY2015Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	9300000
CY2015Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1283500000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	937000
CY2015Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	7000000
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2437846000
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	1883000
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	373042000
CY2015Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	6693000
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	46000
CY2015Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	400000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	11691000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	119334000
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3800000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	11911000
CY2015Q4	us-gaap	Minority Interest MinorityInterest	318000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	428771000
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1552000
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Business Acquisition Equity Interest Issued Or Issuable Value Assigned BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned	7800000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	17856000
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	188956000
CY2015Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	1883000
CY2015Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	2416000
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	738000
CY2015Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	202527000
CY2015Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	14500000
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	25600000
CY2015Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	13096000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	51505000
CY2015Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	3116000
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	220589000
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	82154000
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	28700000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	13662000
CY2015Q4	us-gaap	Assets Assets	4547214000
CY2015Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	83700000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	38639000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	43173000
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	424219000
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	444737000
CY2015Q4	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	1900000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83634000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	48967000
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	219037000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	229300000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	29535000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	527769000
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	12968000
CY2015Q4	us-gaap	Land Land	6683000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	82928000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	567195000
CY2015Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	136600000
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2723000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	66655000
CY2015Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	26382000
CY2015Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	13900000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	424219000
CY2015Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	169903000
CY2015Q4	us-gaap	Goodwill Goodwill	3366150000
CY2015Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	8853000
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9639000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51572000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	34600000
CY2015Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	63288000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	202968000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	25600000
CY2015Q4	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	60383000
CY2015Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1574038000
CY2015Q4	us-gaap	Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount	2905000
CY2015Q4	md	Unamortized Debt Issuance Expense Noncurrent UnamortizedDebtIssuanceExpenseNoncurrent	13096000
CY2015Q4	md	Debt Instrument Face Amount Non Current DebtInstrumentFaceAmountNonCurrent	1273500000
CY2015Q4	md	Debt Instrument Face Amount Current DebtInstrumentFaceAmountCurrent	10000000
CY2015Q4	md	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	311303000
CY2015Q4	md	Line Of Credit Facility Reduction In Available Balance LineOfCreditFacilityReductionInAvailableBalance	200000
CY2015Q4	md	Accrued Professional Liability AccruedProfessionalLiability	60100000
CY2015Q4	md	Unamortized Debt Issuance Expense Current UnamortizedDebtIssuanceExpenseCurrent	0
CY2015Q4	md	Long Term Debt Maturities Repayments Of Principal After Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour	750000000
CY2015Q4	md	Accrued Payroll Taxes And Benefits Current AccruedPayrollTaxesAndBenefitsCurrent	58979000
CY2015Q4	md	Accrued Contingent Consideration Liability Current AccruedContingentConsiderationLiabilityCurrent	13565000
CY2015Q4	md	Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent	395807000
CY2015Q4	md	Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit	919320000
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	93800921	shares
CY2015Q4	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	2500000	shares
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.78
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0002	pure
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	405398000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0027	pure
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35000	shares
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0048	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500	pure
CY2013	us-gaap	Malpractice Loss Contingency Period Increase Decrease MalpracticeLossContingencyPeriodIncreaseDecrease	19797000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0263	pure
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100969000	shares
CY2013	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1857000	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99112000	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	46.48
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.83
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3744	pure
CY2013	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	99000
CY2013	us-gaap	Net Income Loss NetIncomeLoss	280517000
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31288000
CY2013	us-gaap	Profit Loss ProfitLoss	280517000
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	338000
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	448412000
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	28697000
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-212000
CY2013	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	51863000
CY2013	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	238045000
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	452131000
CY2013	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3541000
CY2013	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	20802000
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3719000
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	37331000
CY2013	us-gaap	Investment Income Net InvestmentIncomeNet	1696000
CY2013	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2154012000
CY2013	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	18981000
CY2013	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	126411000
CY2013	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	19000000
CY2013	us-gaap	Interest Paid Net InterestPaidNet	3312000
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2955000
CY2013	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1028500000
CY2013	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	15654000
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	167895000
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	31288000
CY2013	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	10739000
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	38000
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	14784000
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1136000
CY2013	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	18173000
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	26400000
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9857000
CY2013	us-gaap	Operating Expenses OperatingExpenses	1701881000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	33300000
CY2013	us-gaap	Interest Expense InterestExpense	5415000
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-263490000
CY2013	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	11011000
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-132051000
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	49239000
CY2013	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	18579000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	35400000
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	24500000
CY2013	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3656000
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	15920000
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28697000
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	29800000
CY2013	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1211000
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	17037000
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31300000
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	218209000
CY2013	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	911500000
CY2013	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	5772000
CY2013	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	11480000
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	134938000
CY2013	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	51863000
CY2013	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	18900000
CY2013	us-gaap	Depreciation Depreciation	15500000
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	39966000
CY2013	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	149722000
CY2013	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1425000
CY2013	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	741000
CY2013	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	41235000
CY2013	md	Malpractice Loss Contingency Provision For Losses MalpracticeLossContingencyProvisionForLosses	33135000
CY2013	md	Contractual Adjustments And Uncollectibles ContractualAdjustmentsAndUncollectibles	4695232000
CY2013	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	-8100000
CY2013	md	Hospital Contract Administrative Fees HospitalContractAdministrativeFees	146760000
CY2013	md	Payment Of Contingent Consideration Liability Financing PaymentOfContingentConsiderationLiabilityFinancing	10365000
CY2013	md	Payment Of Contingent Consideration Liability Operating PaymentOfContingentConsiderationLiabilityOperating	1308000
CY2013	md	Health Organization Revenue Gross HealthOrganizationRevenueGross	6702484000
CY2013	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	82388000
CY2013	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	1361318000
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.18
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0015	pure
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	422641000
CY2014	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	382500000
CY2014	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	3.46
CY2014	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	3.50
CY2014	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	13	Acquisition
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0033	pure
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1000	shares
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0059	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500	pure
CY2014	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	99887000	shares
CY2014	us-gaap	Malpractice Loss Contingency Period Increase Decrease MalpracticeLossContingencyPeriodIncreaseDecrease	9284000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0274	pure
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99887000	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1299000	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98588000	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	57.73
CY2014	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	98588000	shares
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.22
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3763	pure
CY2014	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	159000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	317281000
CY2014	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	345517000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31719000
CY2014	us-gaap	Profit Loss ProfitLoss	317203000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1506000
CY2014	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	488429000
CY2014	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	479394000
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	512999000
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2137000
CY2014	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	488600000
CY2014	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	26884000
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4383000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	57018000
CY2014	us-gaap	Investment Income Net InvestmentIncomeNet	2728000
CY2014	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2438913000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	17479000
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	40000
CY2014	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	4281000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	508616000
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	42876000
CY2014	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	161841000
CY2014	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	2945493000
CY2014	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1244000
CY2014	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	17500000
CY2014	us-gaap	Interest Paid Net InterestPaidNet	7323000
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3750000
CY2014	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1213500000
CY2014	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	18061000
CY2014	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1780000
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	191413000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	31719000
CY2014	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	13290000
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2262000
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	297000
CY2014	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	21406000
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	27800000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	16791000
CY2014	us-gaap	Operating Expenses OperatingExpenses	1925914000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	28200000
CY2014	us-gaap	Interest Expense InterestExpense	8891000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-503604000
CY2014	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	20735000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	97754000
CY2014	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-417000
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2559000
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	42876000
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	34300000
CY2014	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2492000
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	21109000
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	66039000
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31700000
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	247527000
CY2014	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1754500000
CY2014	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	6998000
CY2014	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	13583000
CY2014	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	1025000
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	167745000
CY2014	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	17462000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	38800000
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	30100000
CY2014	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	488429000
CY2014	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	30100000
CY2014	us-gaap	Depreciation Depreciation	15900000
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45990000
CY2014	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	170007000
CY2014	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1527000
CY2014	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	293000
CY2014	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-78000
CY2014	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	39386000
CY2014	md	Malpractice Loss Contingency Provision For Losses MalpracticeLossContingencyProvisionForLosses	23261000
CY2014	md	Contractual Adjustments And Uncollectibles ContractualAdjustmentsAndUncollectibles	5403437000
CY2014	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	-16125000
CY2014	md	Hospital Contract Administrative Fees HospitalContractAdministrativeFees	179794000
CY2014	md	Payment Of Contingent Consideration Liability Financing PaymentOfContingentConsiderationLiabilityFinancing	11740000
CY2014	md	Payment Of Contingent Consideration Liability Operating PaymentOfContingentConsiderationLiabilityOperating	4071000
CY2014	md	Health Organization Revenue Gross HealthOrganizationRevenueGross	7662556000
CY2014	md	Contributions From Noncontrolling Interest ContributionsFromNoncontrollingInterest	1025000
CY2014	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	89002000
CY2014	md	Increase In Uncertain Tax Position IncreaseInUncertainTaxPosition	2300000
CY2014	md	Stock Issued During Period Value Restricted Stock Contingent Consideration StockIssuedDuringPeriodValueRestrictedStockContingentConsideration	705000
CY2014	md	Number Of Physician Group Practices Acquired NumberOfPhysicianGroupPracticesAcquired	11	Company
CY2014	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	1543395000
CY2014	md	Payments To Acquire Businesses Net Of Cash Acquired Excluding Prior Period Adjustments PaymentsToAcquireBusinessesNetOfCashAcquiredExcludingPriorPeriodAdjustments	479400000
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.58
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0041	pure
CY2015	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.    General:</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The principal business activity of MEDNAX, Inc. (“MEDNAX” or the “Company”) and its subsidiaries is to provide neonatal, anesthesia, maternal-fetal and other pediatric subspecialties physician services. The Company has contracts with affiliated business corporations or professional associations, limited liability companies and partnerships (“affiliated professional contractors”), which are separate legal entities that provide physician services in certain states and Puerto Rico. The Company and its affiliated professional contractors also have contracts with hospitals and other healthcare facilities to provide physician services, which include <font style="WHITE-SPACE: nowrap">(i) fee-for-service</font> contracts, whereby hospitals agree, in exchange for the Company’s services, to authorize the Company and its healthcare professionals to bill and collect the charges for medical services rendered by the Company’s affiliated healthcare professionals, and (ii) administrative fee contracts, whereby the Company is assured a minimum revenue level.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In addition to the Company’s national physician network, during 2015 the Company acquired a radiology physician services and telemedicine company that provides outsourced radiology and telemedicine services to hospital, health system and radiology group facilities as well as a third-party receivables company that specializes in revenue recovery on accounts that require heightened expertise, labor and capital. During 2014, the Company acquired two complementary businesses that offer services to medical providers, including its own, consisting of a revenue cycle management company and a consulting services company.</font></p> </div>
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	368701000
CY2015	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	590000000
CY2015	us-gaap	Line Of Credit Facility Description LineOfCreditFacilityDescription	At the Company’s option, borrowings under the Credit Agreement (other than swingline loans) will bear interest at (i) the Alternate Base Rate (defined as the higher of (a) the prime rate, (b) the Federal Funds Rate plus 1/2 of 1.00% and (c) LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on the Company’s consolidated leverage ratio or (ii) the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on the Company’s consolidated leverage ratio. Swingline loans will bear interest at the alternate base rate plus the applicable margin.
CY2015	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	3.66
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	483423	shares
CY2015	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	3.69
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	12	Acquisition
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0034	pure
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0000893949
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y8M12D
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	29974	shares
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y8M12D
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0043	pure
CY2015	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	710702	shares
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500	pure
CY2015	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	93960000	shares
CY2015	us-gaap	Malpractice Loss Contingency Period Increase Decrease MalpracticeLossContingencyPeriodIncreaseDecrease	-2064000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0029	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0297	pure
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2019-10-29
CY2015	dei	Entity Registrant Name EntityRegistrantName	MEDNAX, INC.
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93960000	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	883000	shares
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	44.43
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	26.58
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93077000	shares
CY2015	us-gaap	Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued	114306	shares
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	55.77
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	70.44
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Accounting Estimates and Assumptions</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are involved in the calculation of the Company’s allowance for contractual adjustments and uncollectibles on accounts receivable, liabilities for self-insured amounts and claims incurred but not reported related to the Company’s professional liability risks, the fair value of goodwill, and liabilities for uncertain tax positions. Actual results could differ from those estimates.</font></p> </div>
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	228707	shares
CY2015	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	93077000	shares
CY2015	dei	Trading Symbol TradingSymbol	MD
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.61
CY2015	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	3400000	shares
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3776	pure
CY2015	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2015	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	226100000
CY2015	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	2171000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	336320000
CY2015	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	343575000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32129000
CY2015	us-gaap	Profit Loss ProfitLoss	335691000
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4905000
CY2015	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	235051000
CY2015	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	818903000
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	557868000
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1639000
CY2015	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	853300000
CY2015	us-gaap	Payments For Previous Acquisition PaymentsForPreviousAcquisition	14300000
CY2015	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	33980000
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18139000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	55391000
CY2015	us-gaap	Investment Income Net InvestmentIncomeNet	1844000
CY2015	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2779996000
CY2015	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Fair Value1 BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1	7700000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	11583000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	467000
CY2015	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	14190000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	539729000
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	20128000
CY2015	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	181005000
CY2015	us-gaap	Stock Issued1 StockIssued1	7800000
CY2015	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1800000
CY2015	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	2946467000
CY2015	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	3135000
CY2015	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	11600000
CY2015	us-gaap	Interest Paid Net InterestPaidNet	20367000
CY2015	us-gaap	Business Combination Separately Recognized Transactions Net Gains And Losses BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses	0
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3675000
CY2015	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2156000000
CY2015	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	27073000
CY2015	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3127000
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	204038000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	32129000
CY2015	us-gaap	Goodwill Transfers GoodwillTransfers	7200000
CY2015	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	13835000
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	500000
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1168000
CY2015	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	2062000
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	12866000
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1628000
CY2015	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	22576000
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	31600000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3644000
CY2015	us-gaap	Operating Expenses OperatingExpenses	2222128000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	31600000
CY2015	us-gaap	Interest Expense InterestExpense	23110000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-848000000
CY2015	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	31956000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	482943000
CY2015	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	13000
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	14494000
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20128000
CY2015	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	39700000
CY2015	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2654000
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	20948000
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7874000
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32100000
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	305915000
CY2015	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2121500000
CY2015	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-4101000
CY2015	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	15217000
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	168596000
CY2015	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	11583000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	11300000
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42000000
CY2015	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	23000000
CY2015	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	235051000
CY2015	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	750000000
CY2015	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	6100000
CY2015	us-gaap	Depreciation Depreciation	22200000
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	64228000
CY2015	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	181462000
CY2015	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1692000
CY2015	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	1382000
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-629000
CY2015	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	39204000
CY2015	md	Malpractice Loss Contingency Provision For Losses MalpracticeLossContingencyProvisionForLosses	13407000
CY2015	md	Contractual Adjustments And Uncollectibles ContractualAdjustmentsAndUncollectibles	6389195000
CY2015	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	-25797000
CY2015	md	Business Combination Contingent Consideration Arrangement Time Period Of Measurement BusinessCombinationContingentConsiderationArrangementTimePeriodOfMeasurement	P2Y
CY2015	md	Hospital Contract Administrative Fees HospitalContractAdministrativeFees	226234000
CY2015	md	Payment Of Contingent Consideration Liability Financing PaymentOfContingentConsiderationLiabilityFinancing	12856000
CY2015	md	Payment Of Contingent Consideration Liability Operating PaymentOfContingentConsiderationLiabilityOperating	1439000
CY2015	md	Health Organization Revenue Gross HealthOrganizationRevenueGross	8942957000
CY2015	md	Business Acquisition Contingent Consideration At Fair Value Decrease BusinessAcquisitionContingentConsiderationAtFairValueDecrease	1000000
CY2015	md	Business Combination Contingent Consideration Arrangements Time Period BusinessCombinationContingentConsiderationArrangementsTimePeriod	P5Y
CY2015	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	98480000
CY2015	md	Increase In Uncertain Tax Position IncreaseInUncertainTaxPosition	1200000
CY2015	md	Assumed Payment Probability Of Contingent Consideration Payment AssumedPaymentProbabilityOfContingentConsiderationPayment	1.00	pure
CY2015	md	Number Of Physician Group Practices Acquired NumberOfPhysicianGroupPracticesAcquired	10	Company
CY2015	md	Number Of Anesthesiology Practices Acquired NumberOfAnesthesiologyPracticesAcquired	7	Company
CY2015	md	Number Of Neonatology Practices Acquired NumberOfNeonatologyPracticesAcquired	2	Company
CY2015	md	Number Of Other Pediatric Subspecialty Practices Acquired NumberOfOtherPediatricSubspecialtyPracticesAcquired	1	Company
CY2015	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	1753505000
CY2015	md	Payments To Acquire Businesses Net Of Cash Acquired Excluding Prior Period Adjustments PaymentsToAcquireBusinessesNetOfCashAcquiredExcludingPriorPeriodAdjustments	818300000
CY2015	md	Stock Issued During Period Value Restricted Stock Acquisition Consideration StockIssuedDuringPeriodValueRestrictedStockAcquisitionConsideration	7800000
CY2015	md	Number Of Non Practice Business Acquired NumberOfNonPracticeBusinessAcquired	2	Acquisition
CY2015	md	Accrued Professional Liabilities Assumed Through Acquisition AccruedProfessionalLiabilitiesAssumedThroughAcquisition	35968000
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100696000	shares
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99076000	shares
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	63660000
CY2014Q1	us-gaap	Profit Loss ProfitLoss	63660000
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	104097000
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	264000
CY2014Q1	us-gaap	Investment Income Net InvestmentIncomeNet	1635000
CY2014Q1	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	566338000
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	104361000
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40701000
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	462241000
CY2014Q1	us-gaap	Interest Expense InterestExpense	1371000
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	58414000
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10370000
CY2014Q1	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	21417000
CY2014Q1	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	372040000
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.72
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95325000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94231000	shares
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.73
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	68707000
CY2015Q1	us-gaap	Profit Loss ProfitLoss	68589000
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	114821000
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2304000
CY2015Q1	us-gaap	Investment Income Net InvestmentIncomeNet	142000
CY2015Q1	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	639395000
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	112517000
CY2015Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	821000
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43928000
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	524574000
CY2015Q1	us-gaap	Interest Expense InterestExpense	3267000
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	67936000
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13612000
CY2015Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-118000
CY2015Q1	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	23431000
CY2015Q1	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	419595000
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99866000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98411000	shares
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.80
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	79016000
CY2014Q2	us-gaap	Profit Loss ProfitLoss	79025000
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	129672000
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1703000
CY2014Q2	us-gaap	Investment Income Net InvestmentIncomeNet	335000
CY2014Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	595544000
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	127969000
CY2014Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	150000
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	48944000
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	465872000
CY2014Q2	us-gaap	Interest Expense InterestExpense	2188000
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60829000
CY2014Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10361000
CY2014Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	9000
CY2014Q2	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	22466000
CY2014Q2	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	372216000
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.90
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93495000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92500000	shares
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.91
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	84130000
CY2015Q2	us-gaap	Profit Loss ProfitLoss	84048000
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	140957000
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4020000
CY2015Q2	us-gaap	Investment Income Net InvestmentIncomeNet	384000
CY2015Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	676588000
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	136937000
CY2015Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	745000
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52889000
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	535631000
CY2015Q2	us-gaap	Interest Expense InterestExpense	5149000
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	72401000
CY2015Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15549000
CY2015Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-82000
CY2015Q2	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	24878000
CY2015Q2	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	422803000
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.86
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100145000	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99088000	shares
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.87
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	86207000
CY2014Q3	us-gaap	Profit Loss ProfitLoss	86238000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	138143000
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-731000
CY2014Q3	us-gaap	Investment Income Net InvestmentIncomeNet	563000
CY2014Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	626506000
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	137412000
CY2014Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	725000
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51174000
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	488363000
CY2014Q3	us-gaap	Interest Expense InterestExpense	2019000
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60643000
CY2014Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11356000
CY2014Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	31000
CY2014Q3	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	21570000
CY2014Q3	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	394794000
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.97
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93646000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92949000	shares
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.98
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	90781000
CY2015Q3	us-gaap	Profit Loss ProfitLoss	90640000
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	151130000
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4850000
CY2015Q3	us-gaap	Investment Income Net InvestmentIncomeNet	567000
CY2015Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	722273000
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	146280000
CY2015Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	784000
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	55640000
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	571143000
CY2015Q3	us-gaap	Interest Expense InterestExpense	6201000
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	80185000
CY2015Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16918000
CY2015Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-141000
CY2015Q3	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	24007000
CY2015Q3	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	450033000
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.89
CY2014Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99129000	shares
CY2014Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98066000	shares
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.90
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	88398000
CY2014Q4	us-gaap	Profit Loss ProfitLoss	88280000
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	141087000
CY2014Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2213000
CY2014Q4	us-gaap	Investment Income Net InvestmentIncomeNet	195000
CY2014Q4	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	650525000
CY2014Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	138874000
CY2014Q4	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	905000
CY2014Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	50594000
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	509438000
CY2014Q4	us-gaap	Interest Expense InterestExpense	3313000
CY2014Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	67641000
CY2014Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13903000
CY2014Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-118000
CY2014Q4	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	23549000
CY2014Q4	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	404345000
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.99
CY2015Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93536000	shares
CY2015Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92790000	shares
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.00
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	92702000
CY2015Q4	us-gaap	Profit Loss ProfitLoss	92414000
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	150960000
CY2015Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6965000
CY2015Q4	us-gaap	Investment Income Net InvestmentIncomeNet	751000
CY2015Q4	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	741740000
CY2015Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	143995000
CY2015Q4	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	777000
CY2015Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51581000
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	590780000
CY2015Q4	us-gaap	Interest Expense InterestExpense	8493000
CY2015Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	85393000
CY2015Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18149000
CY2015Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-288000
CY2015Q4	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	26164000
CY2015Q4	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	461074000

Files In Submission

Name	View Source	Status
0001193125-16-459842-index-headers.html	Edgar Link	pending
0001193125-16-459842-index.html	Edgar Link	pending
0001193125-16-459842.txt	Edgar Link	pending
0001193125-16-459842-xbrl.zip	Edgar Link	pending
d126581d10k.htm	Edgar Link	pending
d126581dex211.htm	Edgar Link	pending
d126581dex231.htm	Edgar Link	pending
d126581dex311.htm	Edgar Link	pending
d126581dex312.htm	Edgar Link	pending
d126581dex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g126581g70x96.jpg	Edgar Link	pending
md-20151231.xml	Edgar Link	completed
md-20151231.xsd	Edgar Link	pending
md-20151231_cal.xml	Edgar Link	unprocessable
md-20151231_def.xml	Edgar Link	unprocessable
md-20151231_lab.xml	Edgar Link	unprocessable
md-20151231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MD
Pediatrix Medical Group, Inc. Stock $md

2015 Form 10-K Financial Statement

#000119312516459842 Filed on February 11, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MD Pediatrix Medical Group, Inc. Stock $md

2015 Form 10-K Financial Statement

#000119312516459842 Filed on February 11, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MD
Pediatrix Medical Group, Inc. Stock $md